To OTC Journal Members:
 

A Look Ahead

It's November 1st. There are two months left in the year. It's time to start wrapping up 2003 and making plans to introduce new and exciting features and ideas in 2004.

Before the end of the year there may be one or two new companies covered. I'm still looking for an undiscovered and under followed microcap stock in the biotech arena. November and December are generally the best months of the year to be in the market, and a good time to rack up profits.

We're going to do a series of audio interviews with management at each of the companies I follow before year's end. When the edition comes, you will be able to click on a link in the OTC Journal and listen to the interview streamed over the internet. If you don't have speakers or headphones you will be able to read a transcribed printed version. If you are a shareholder or thinking of becoming one of any of these companies, this will give you an opportunity to form your own opinion about the people that run these companies. Over the long term, their ability to execute their business plan equates to profits or losses. This will help you decide if you want to make any adjustments in your portfolio before the end of the year.

I will no doubt drop some companies from coverage. I tend to drop the ones that aren't working out- Most investors make the mistake of selling their winners and holding on to their losers. Since nearly all of my ideas are in the speculative end of the market there are going to be losers. You have to accept that fact. Learning to handle losers is just as important as finding winners to be a successful investor. If you can't handle losses this is not the newsletter for you.

Looking forward, he's something very important you need to act on:
 

Join The Preferred Member List

We're offering a preferred members list. Joining the list is free for the remainder of this year. There will be significant and important benefits associated with preferred membership in the future.

Some of the benefits we're considering include:

• Early delivery "ahead of the crowd" of the OTC Journal with special features.
• Access to a special preferred email address or chat room for questions.
• A larger variety of specialized content which may include less speculative ideas in both growth and income, more short term trades, and more technical analysis.
• Articles from well known guest authors.
• Access to specially negotiated discounts members.
• Numerous other features to be announced- your input is welcome. Email editor@otcjournal.com.

Benefits for Preferred Members will begin next year. 

Your email address will never be given to anyone for any purpose. We adhere to a strict privacy policy, and will continue to do so. The unsubscribe link you find at the bottom of every one of our editions works flawlessly, and you can opt out any time you decide you want cancel your membership.

Please sign up immediately so we can begin to plan special features for our preferred members.

Click Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts.

All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

The editor, members of the editor's family, and/or entities with which they are affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.

The profiles, critiques, and other editorial content of the OTCjournal.com may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID:$subst('Recip.userid') Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.